MAIA Biotechnology financials
$1.15−2.54%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$8.3M | -$6.9M | -$4.3M | -$9.4M | -$5.2M | -$5.4M | -$5.0M | -$4.2M | -$3.8M | -$3.9M | -$6.4M | -$5.0M |
| Net income | -$7.9M | -$6.4M | -$3.6M | -$8.9M | -$5.3M | -$4.5M | -$3.6M | -$2.7M | -$8.9M | -$8.1M | -$6.3M | -$4.9M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.13 | $-0.14 | $-0.10 | $-0.27 | $-0.18 | $-0.16 | $-0.14 | $-0.11 | $-0.40 | $-0.46 | $-0.40 | $-0.36 |
| EBITDA | -$8.3M | -$6.9M | -$4.3M | -$9.4M | -$5.2M | -$5.4M | -$5.0M | -$4.2M | -$3.8M | -$3.9M | -$6.4M | -$5.0M |
| Operating cash flow | -$6.8M | -$5.3M | -$7.0M | -$3.5M | -$4.1M | -$4.2M | -$3.9M | -$3.5M | -$4.7M | -$3.6M | -$4.0M | -$3.2M |
| Free cash flow | -$6.8M | -$5.3M | -$7.0M | -$3.5M | -$4.1M | -$4.2M | -$3.9M | -$3.5M | -$4.7M | -$3.6M | -$4.0M | -$3.2M |
| Diluted shares | 60.8M | 45.2M | 37.3M | 33.2M | 30.3M | 27.7M | 25.1M | 23.9M | 22.2M | 17.6M | 15.5M | 13.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $27.6M | $34.4M | $8.7M | $10.9M | $10.1M | $10.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $28.2M | $35.3M | $9.7M | $11.8M | $11.0M | $11.9M |
| Total liabilities | $7.6M | $7.6M | $7.3M | $11.7M | $7.2M | $6.9M |
| Shareholders' equity | $20.7M | $27.8M | $2.4M | $41.7K | $3.9M | $4.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology